A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC
Condition(s):HER2 Positive Metastatic Breast CancerLast Updated:June 14, 2021Completed
Hide Studies Not Open or Pending
Condition(s):HER2 Positive Metastatic Breast CancerLast Updated:June 14, 2021Completed
Condition(s):Metastatic Breast Cancer; Advanced Breast Cancer; HER2-positive Breast CancerLast Updated:July 11, 2022Withdrawn
Condition(s):Gastric Cancer; Stomach Cancer; Esophageal CancerLast Updated:August 4, 2022Completed
Condition(s):HER2-positive Breast Cancer; HER2-positive CarcinomaLast Updated:February 22, 2022Approved for marketing
Condition(s):Breast CancerLast Updated:February 10, 2022Completed
Condition(s):HER-2 Positive Breast Cancer; Metastatic NeoplasmLast Updated:November 23, 2022Completed
Condition(s):Breast Cancer MetastaticLast Updated:August 22, 2023Active, not recruiting
Condition(s):Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer; HER2-positive Breast CancerLast Updated:July 18, 2023Recruiting
Condition(s):Gastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric CancerLast Updated:December 26, 2023Active, not recruiting
Condition(s):Breast Cancer; Gastric CancerLast Updated:October 19, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.